

<u>AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs</u>

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0020
Drug name and formulations:	Renavit [®] B-complex plus C Water-soluble vitamin

Criteria	Example	Committee Consensus
Patient Safety	Potential for abuse, toxicity, significant drug interactions	Water soluble vitamin supplement. Low risk.
Clinical effectiveness	Established licensed product	Moderate effect as evidenced by DOPPS study.
Strength of evidence		No randomised controlled trials but a large observational study (DOPPS) which demonstrated a significant lower mortality risk despite methodological difficulties (potential for confounding factors).
Cost effectiveness or resource impact	£	Cost effective compared to alternative preparations such as Ketovite®. It also offers a lower tablet burden and does not require refrigeration.
Place of therapy relative to available treatments	1/2 nd tier	1 st line and replace current treatment options.
National guidance and priorities	NICE, MTRAC	No NICE or MTRAC guidelines. Renal association guidelines on nutrition in CKD recommend that haemodialysis patients should be prescribed a supplement of water soluble vitamins.
Local health priorities	CCG views	None
Equity of access	Equality assessment	None



Stakeholder views	Define wider groups to be engaged	None
Implementation requirements	Requires, RICAD ESCA etc.	None

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	Add Renavit® to APC formulary as GREEN, remove Ketovite® from APC formulary. Despite the lack of robust evidence, guidance acknowledges vitamin provision as a low cost, low risk practice which may reduce morbidity and mortality.
Implementation requirements:	
Implementation monitoring:	